The Difference Between a Biosimilar and a Generic — What Hospital Pharmacists Need to Know

In hospital pharmacy conversations across India, two words get used interchangeably more often than they should: generic and biosimilar. Both refer to non-originator versions of existing medicines. Both are generally less expensive than the originator product. And both require regulatory approval before they can be sold. But beyond those surface similarities, the two are fundamentally different — in how they are made, what regulatory approval actually means for each, and what the clinical implications of substitution are.

For hospital pharmacists and procurement teams, understanding this distinction is not an academic exercise. It has direct consequences for procurement decisions, for conversations with clinicians about substitution, and for the documentation trail that protects the hospital if a question about product equivalence ever arises.

What Is a Generic Medicine?

A generic medicine contains the same active ingredient as the originator brand, at the same dose, in the same dosage form, and is administered by the same route. It is manufactured by a different company — typically after the originator’s patent has expired — and must demonstrate bioequivalence to the originator through pharmacokinetic studies showing that the generic is absorbed at the same rate and to the same extent as the reference product.

The key word here is equivalence — and for conventional small-molecule medicines, equivalence is achievable because the active ingredient is a defined chemical entity. Metformin is Metformin. Atorvastatin is Atorvastatin. Whether it is manufactured by Pfizer or by a generic manufacturer in Ahmedabad, the molecule is identical — same molecular structure, same pharmacological activity, same clinical effect.

This is why generic substitution for small-molecule medicines is generally straightforward and widely practised in hospital formularies across India. The molecule is the same. The bioequivalence has been demonstrated. The clinical effect is equivalent.

Indian pharmaceutical manufacturers including Sun Pharma, Cipla, Dr. Reddy’s, and Lupin are among the world’s largest producers of generic small-molecule medicines — supplying not just the Indian market but a significant proportion of the global market for essential medicines. This is India’s strength in pharmaceuticals, and it is built on the straightforward chemistry of small-molecule generic equivalence.

The Central Drugs Standard Control Organisation (CDSCO) regulates generic medicine approvals in India, requiring demonstration of pharmaceutical equivalence and bioequivalence before a generic can receive marketing authorisation.

What Is a Biosimilar?

A biosimilar is where the comparison with generics ends — and where the complexity begins.

A biosimilar is a biological medicine that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in terms of safety, purity, and potency. The distinction that matters is in how biologics are made — and why that makes “highly similar” the most precision can ever achieve.

Biologics — including monoclonal antibodies like Dupixent (Dupilumab), Tishtha (Nivolumab), Xolair (Omalizumab), and Betrecep (Bevacizumab) — are not synthesised chemically. They are produced by living cells — typically engineered mammalian cells grown in large bioreactors — and the resulting molecules are extraordinarily complex. A monoclonal antibody has a molecular weight approximately 1,000 times greater than a small-molecule drug, with intricate three-dimensional structures, post-translational modifications including glycosylation patterns, and subtle structural features that vary depending on the specific cell line used, the culture conditions, and the manufacturing process.

Because the manufacturing process is inseparable from the product itself, a biosimilar manufacturer cannot simply replicate the originator’s molecule — they develop their own cell line, their own manufacturing process, and their own molecule that is as similar as possible to the reference biologic. The result is highly similar — close enough to be clinically equivalent in safety, purity, and potency — but not structurally identical.

This is why the regulatory pathway for biosimilars is fundamentally more demanding than for small-molecule generics. Demonstrating bioequivalence through pharmacokinetic studies is not sufficient. A biosimilar must demonstrate biosimilarity through an extensive analytical characterisation programme comparing the biosimilar to the reference biologic across hundreds of structural and functional attributes, supplemented by comparative clinical pharmacology, safety, and efficacy data.

The World Health Organization biosimilar guidelines and the European Medicines Agency biosimilar regulatory framework provide the most comprehensive international reference for biosimilar development and approval standards.

The Three Practical Differences That Matter for Hospital Pharmacists

1. Manufacturing complexity — and what it means for quality assurance

Small-molecule generics are manufactured through defined chemical synthesis routes. Quality control is straightforward — analytical testing confirms that the molecule is chemically identical to the reference product. A generic Metformin tablet either contains Metformin or it does not. The quality assurance is binary.

Biologic and biosimilar manufacturing is not binary. Cell culture conditions, purification processes, storage conditions, and shipping temperatures all affect the final product. A biologic that has been manufactured correctly but stored incorrectly — even briefly — may have different structural characteristics than a compliant product. The glycosylation pattern of a monoclonal antibody is exquisitely sensitive to manufacturing and storage conditions in ways that a small-molecule drug is not.

This is why cold chain compliance matters so much more for biologics than for conventional medicines. And it is why sourcing biosimilars and originator biologics through licensed specialty pharmaceutical distributors with verified cold chain infrastructure is not optional — it is a clinical necessity. As one of Delhi’s trusted pharmaceutical distribution companies, A.K. Pharma maintains cold chain storage and last-mile delivery for all biologic products including Denorange (Denosumab), Luprodex (Leuprolide Acetate), Bdparib (Rucaparib), and the full range of oncology and immunology biologics in its portfolio.

2. Substitution — not as simple as it is for generics

For small-molecule generics, automatic substitution at the pharmacy level is widely practised — a pharmacist can dispense a generic instead of the branded originator without consulting the prescribing physician in many formulary systems, because bioequivalence has been demonstrated and the molecules are identical.

For biosimilars, the situation is different. Whether a biosimilar can be automatically substituted for an originator biologic — or substituted between biosimilars of the same reference product — is a clinical and regulatory question that varies by country, by specific biosimilar, and by indication. In India, the CDSCO’s guidance on biosimilar substitution continues to evolve. In clinical practice, most specialist physicians prefer to be involved in any decision to switch a patient from an originator biologic to a biosimilar, or between biosimilars — particularly for patients whose disease is stable on their current treatment.

Hospital procurement teams should understand that “we have switched to a biosimilar of the same medicine” is a conversation that needs to happen with the treating clinician before the switch, not after the new product has been dispensed.

3. Clinical evidence — indication extrapolation vs proven equivalence per indication

When a small-molecule generic demonstrates bioequivalence to the reference product, that equivalence applies to all the approved indications of the reference product — there is no indication-specific question because the molecule is the same.

For biosimilars, regulatory agencies apply a principle called extrapolation — a biosimilar approved on the basis of clinical data in one indication may be approved for all the indications of the reference biologic, on the grounds that the demonstration of biosimilarity in one indication provides sufficient evidence of equivalence across others. This is a scientifically sound and well-established regulatory approach, but it does mean that for some biosimilars the clinical data directly supporting use in every extrapolated indication is limited. This is not a reason to avoid biosimilars — they have an excellent global safety and efficacy track record — but it is context that treating physicians may consider when making switching decisions for individual patients.

The Indian Pharmacopoeia Commission and CDSCO’s biosimilar guidelines provide the regulatory framework applicable to biosimilar approval and substitution in India.

Examples From A.K. Pharma’s Range — Where This Distinction Applies in Practice

Several medicines in A.K. Pharma’s product range exist as both originator biologics and Indian biosimilars or generics, and understanding the distinction helps procurement teams make informed sourcing decisions:

Denosumab — originator vs Indian versions
The originator Denosumab brands — Prolia (60mg for osteoporosis) and Xgeva (120mg for bone metastases) — are manufactured by Amgen. Indian versions including Denorange and Denaxa are biosimilars manufactured by Indian companies. Both originator and biosimilar versions are available through A.K. Pharma. The treating physician specifies which is prescribed.

Bevacizumab — originator and biosimilar
The originator Bevacizumab (Avastin, Roche) and Indian biosimilar versions including Betrecep are both available. In Indian oncology practice, Bevacizumab biosimilars are widely used and have an established track record.

Capecitabine — small-molecule generic, simple substitution
Capecite (Capecitabine 500mg) is a small-molecule generic of the originator Xeloda — same active ingredient, same dose, bioequivalent. This is a straightforward generic substitution with no biosimilar complexity.

Rucaparib — small-molecule generic
Bdparib (Rucaparib) — available in 200mg and 300mg — is the Indian generic of originator Rubraca. Small molecule, same active ingredient, same mechanism — a conventional generic.

This contrast is exactly what hospital formulary teams encounter in practice: some oncology medicines are straightforward small-molecule generics where substitution is uncomplicated, and others are biologics where biosimilarity has been established but the substitution conversation requires clinical input.

What the Procurement Team Should Do in Practice

For small-molecule generics: Standard formulary substitution policies apply. Confirm that the generic has CDSCO approval and is sourced from a reputable licensed distributor with full batch documentation. The molecule is equivalent — procurement can proceed on that basis.

For biosimilars: Before switching a patient from an originator biologic to a biosimilar, or between biosimilars — involve the treating specialist. Document the switch in the patient record. Ensure the biosimilar has full CDSCO approval for the relevant indication. Source from a licensed specialty distributor who can provide complete batch documentation and cold chain compliance records. Do not substitute silently at the pharmacy level without clinical involvement.

For all biologics — originator or biosimilar: Cold chain compliance is non-negotiable. Request temperature monitoring documentation with every delivery. A biologic that has been temperature-compromised is not equivalent to a compliant product regardless of what the label says.

A.K. Pharma is a licensed medicine distributor in Delhi and pharmaceutical distributor in Delhi supplying both originator biologics and Indian biosimilars across its product range — with complete batch documentation and cold chain-compliant delivery for every shipment. Among pharmaceutical distribution companies operating in Delhi, A.K. Pharma’s exclusive focus on specialty and imported medicines means that the sourcing relationships, cold chain infrastructure, and documentation standards required for biologic procurement are not a secondary capability — they are the core of what we do.

Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827, or visit akpharma.in to browse the full range.

Frequently Asked Questions

Q. What is the main difference between a generic and a biosimilar?
A generic contains the same chemical molecule as the originator — structurally identical, bioequivalent. A biosimilar is highly similar to the originator biologic but not structurally identical — because biologics are produced by living cells and the manufacturing process is part of the product. The regulatory requirements for biosimilar approval are significantly more demanding than for small-molecule generics.

Q. Can a biosimilar be automatically substituted for an originator biologic in India?
This is a clinical and regulatory question that requires involvement of the treating specialist. Unlike small-molecule generic substitution, biosimilar substitution for a stable patient on an originator biologic should not happen at the pharmacy level without clinical input. The prescribing physician should be involved in any switching decision.

Q. Are biosimilars as safe and effective as originator biologics?
Approved biosimilars have demonstrated no clinically meaningful differences in safety, purity, and potency compared to the reference biologic — this is what regulatory approval means. Globally, biosimilars have an excellent safety and efficacy track record with billions of patient-doses administered. The key is that they must have full regulatory approval for the relevant indication and be sourced through verified, cold chain-compliant supply channels.

Q. Why does cold chain matter more for biosimilars and biologics than for conventional medicines?
Biologics are large, complex protein molecules that are sensitive to temperature, light, and mechanical stress. A temperature excursion — even a brief one — can cause aggregation, denaturation, or loss of potency that is invisible at inspection but has real clinical consequences. Small-molecule generics are far more robust to temperature variation.

Q. Is Capecite the same as Xeloda?
Capecite (Capecitabine 500mg) manufactured by Anakaas Life Bio Science is the Indian generic of the originator Xeloda (Roche). Both contain Capecitabine 500mg — this is a straightforward small-molecule generic substitution, not a biosimilar situation. The molecules are chemically identical.

Q. Is Denorange the same as Prolia?
Denorange (Denosumab 60mg) is a biosimilar of the originator Prolia (Denosumab 60mg, Amgen). Both contain Denosumab and have been approved for the same indication. Denorange has demonstrated biosimilarity to the reference product. Substitution should still involve the treating physician — particularly for patients who are stable on Prolia.

Q. Where can hospitals source both originator biologics and biosimilars in India?
A.K. Pharma supplies both originator biologics and approved Indian biosimilars across its product range to hospitals and oncology centres across India. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for specific product availability and pricing.

Disclaimer: This article is intended for general informational and educational purposes only and does not constitute medical, clinical, or regulatory advice. All decisions about biosimilar substitution, formulary policy, and individual patient treatment should be made by qualified healthcare professionals in accordance with applicable regulatory guidelines and clinical practice standards. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.

biologic medicine India, biosimilar India, biosimilar substitution India, Biosimilar vs generic India, generic medicine India, hospital pharmacy India, medicine distributor in Delhi, pharmaceutical distributor Delhi, specialty medicine procurement India